65 results about "Gastrointestinal fluids" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

This invention discloses a probiotic microcapsule and its preparation method, belonging to the field of microcapsule preparation technology. The preparation method includes the following steps: (1) dissolving Sophora japonica extract in water, stirring, adding sodium alginate, and stirring again to obtain a wall material solution; (2) centrifuging and washing the activated probiotics, preparing a bacterial suspension, mixing it with the wall material solution obtained in step (1), stirring, and obtaining a wall material bacterial suspension; (3) adding the wall material bacterial suspension obtained in step (2) to a calcium chloride solution and letting it stand, then adding the formed gel to a chitosan solution, stirring, washing, and obtaining the final product. The preparation process of this invention is simple and convenient, and the raw materials are inexpensive and easy to obtain, which can effectively reduce the production cost of microcapsules, facilitate large-scale industrial production and application promotion, effectively improve the biocompatibility, biodegradability, mechanical strength and encapsulation rate of microcapsules, and enhance the storage stability and resistance to gastrointestinal fluid stress of microcapsules.

According to the invention, the traditional fermented koumiss in Xinjiang is collected, two novel multifunctional probiotic strains, namely, the lactobacillus plantarum SR6 GDMCC NO.66817 strain and the enterococcus faecalis SM5 GDMCC NO.66816 strain with good compatibility are separated and screened out, and the two strains have the characteristics of reducing blood fat, reducing cholesterol, removing triglyceride, resisting oxidation and antagonizing pathogenic bacteria, and have the characteristics of good cholate and gastrointestinal tract tolerance, high survival rate and good safety. The growth characteristics and compatibility of the two strains are improved; the inhibition rate of cholesterol esterase and pancreatic lipase; the method comprises the following steps: evaluating the triglyceride removal rate, antioxidant activity, pathogenic bacterium resistance, artificially simulated gastrointestinal fluid tolerance, strain drug resistance and safety, compounding lactobacillus plantarum SR6 and enterococcus faecalis SM5 strains according to a ratio of 1: 1 to prepare a freeze-dried bacterial agent, and keeping good survival rate (pgt; 0.05) and functional characteristics, the strain can be used as a functional direct vat set starter and is directly applied to production of fermented dairy products, and the biological activity of food is improved.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

Embodiments of devices and methods for sampling gastrointestinal fluids and assessing gastrointestinal function using a device comprising a sampling tube are provided.

The invention belongs to the technical field of microorganisms, and relates to a bifidobacterium breve strain capable of relieving constipation, the strain is bifidobacterium breve Bb-PG-14, the classification name of the strain is Bifidobacterium breve, the preservation number is CGMCC No.31861, the preservation time is September 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, and the preservation number is CGMCC No.31861. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from excrement of healthy babies, has relatively strong acid resistance, alkali resistance, cholate resistance and artificial simulated gastrointestinal fluid tolerance, and has the characteristics of probiotics.

The invention belongs to the technical field of surgical instruments, and particularly relates to a gastrointestinal fluid decompression device for gastrointestinal surgery, which comprises a shell, a negative pressure assembly, a cleaning assembly and a switching mechanism, the switching mechanism drives the negative pressure assembly and the cleaning assembly to be in butt joint with the butt joint opening in a negative pressure mode and a cleaning mode correspondingly and form negative pressure and release cleaning liquid in a pipeline connected with the butt joint opening correspondingly, the negative pressure assembly is a negative pressure peripheral pump, the cleaning assembly is a liquid conveying screw pump, the switching mechanism comprises a gear ring and a motor, the gear ring is rotationally arranged in the shell, and the motor is arranged in the shell. A transmission gear is arranged on an output shaft of the motor and meshed with the outer side of the gear ring, the inner side of the gear ring is meshed with a rotating shaft of the negative-pressure peripheral pump and a transmission rod of the liquid conveying screw pump, and positive and negative rotation of the gear ring is used for driving the negative-pressure peripheral pump and the liquid conveying screw pump to be switched to the butt joint position of the butt joint opening and driving the rotating shaft and the transmission rod to rotate. The negative pressure can be provided and the pipeline can be cleaned by switching positions.

The application discloses a plant lactobacillus strain and application thereof, and belongs to the technical field of microorganisms. The preservation number of the strain is CGMCC No. 33864. The strain has good tolerance to gastrointestinal juice and bile salts and has no hemolytic activity. Concentrated cell-free supernatant prepared from the strain can inhibit salmonella, including inhibiting the growth of salmonella, killing bacteria, inhibiting or removing biofilm. Animal experiments show that the strain and the concentrated cell-free supernatant thereof can prevent salmonella infection, alleviate weight loss caused by infection, maintain intestinal barrier integrity, reduce the level of pro-inflammatory factors, alleviate tissue damage, improve the expression of colon tight junction proteins and mucin, promote the generation of short-chain fatty acids, and restore the intestinal flora structure. The application further provides a microbial preparation containing the strain and / or the concentrated cell-free supernatant thereof. The strain and the microbial preparation can be used for preparing products for resisting salmonella, preventing salmonella infection or improving intestinal health.

This invention discloses a method for preparing piperine starch microcapsules with sustained-release properties, belonging to the field of food processing technology. Using piperine as the core material, oleic acid as the oil phase carrier, and PG 2000 type octenyl succinate starch ester as the wall material, sustained-release piperine microcapsules are prepared through oil phase preparation, aqueous phase preparation, high-speed shearing, high-pressure homogenization, and spray drying. The microcapsules prepared by this invention have high encapsulation efficiency, small and uniformly distributed reconstituted particle size, and a stable system that is not prone to sedimentation. This allows for the slow and continuous release of piperine in simulated gastrointestinal fluid, significantly improving its poor water solubility, low stability, and low bioavailability. The resulting product can be widely used in the food, health product, and pharmaceutical fields.

The application discloses a plant Lactobacillus rhamnosus microcapsule and a preparation method and application thereof, and the plant Lactobacillus rhamnosus is embedded by adopting a low-temperature spray drying process with lily starch, citrus pectin and whey protein as wall materials, and mainly includes the following steps: preparation of a bacterial suspension, preparation of a wall material solution, preparation of a microcapsule solution and low-temperature spray drying for preparing the microcapsule. The preparation technology of the stable encapsulated plant Lactobacillus rhamnosus microcapsule provided by the application has the advantages that the viable bacterial count in the microcapsule is high after spray drying, the microcapsule has strong gastrointestinal fluid resistance, is stable in storage, and can effectively solve the problem that the bacterial activity of the plant Lactobacillus rhamnosus and products thereof is reduced or even inactivated in the production and processing, storage and transportation and in-vivo digestion process; the prepared microcapsule can be used as a probiotic bacterial agent and applied to foods such as cheese, yogurt, ice cream, milk, chocolate, lactic acid bacterial beverages and baked products, and helps to promote the healthy development of the probiotic industry, and has obvious economic and social benefits.

The invention belongs to the technical field of microorganisms, and relates to a lactobacillus paracasei Lpc-14 strain with functions of resisting oxidation and promoting gastrointestinal motility and a preparation method of the lactobacillus paracasei Lpc-14, the lactobacillus paracasei is classified and named as Lactobacillus paracasei, the preservation number of the lactobacillus paracasei is CGMCC No. 29666, the preservation time is January 18, 2024, and the preservation number of the lactobacillus paracasei Lpc-14 is CGMCC No. 29666. The preservation unit is China General Microbiological Culture Collection Center, and the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from naturally-fermented Chinese sauerkraut fermentation liquor, has the capacity of resisting oxidation and promoting gastrointestinal motility of mice with constipation and improving secretion of gastrointestinal regulating peptides, further has the capacity of resisting acid and alkali and resisting artificial simulated gastrointestinal fluid and bile, and has the characteristics of probiotics.

The invention relates to the technical field of gastrointestinal decompression, and particularly discloses a gastrointestinal fluid decompression device for gastrointestinal surgery, which comprises a bag-shaped container and a connecting pipe, the top of the bag-shaped container is fixedly connected with an upper cover, and the bag-shaped container and the upper cover are internally and fixedly connected with a fixing pipe; firstly, the intubation tube is installed at one end of the connecting tube, the bearing assembly is installed at the top of the bag-shaped container through the fixing tube, the connecting tube is inserted into the bearing assembly through the inserting assembly during use, and the inserting assembly is rotated to enable the intubation tube to be communicated with a movable sleeve discharge opening; the rotary insertion pipe is continuously pressed, the limiting block drives the sealing sleeve to rotate, the insertion pipe is longitudinally fixed, meanwhile, the movable sleeve is driven to be positioned and fixed along the guide block and the guide groove, longitudinal limiting of the rotary insertion pipe is relieved during disassembly, the insertion pipe and the movable sleeve move upwards under the elastic force effect of the reset assembly, and the movable sleeve seals the bottom of the mounting base; the intubation tube is continuously rotated and lifted upwards, the movable sleeve is reset and fixed, the sealing sleeve moves upwards, the top of the bag-shaped container and the port of the connecting tube are synchronously sealed, liquid leakage and dripping are avoided, and the pollution risk is reduced.

The invention discloses an anthocyanin ingredient containing milk fat globules and a preparation method thereof.The preparation method comprises the specific steps that the milk fat globules are extracted from fresh raw milk, anthocyanin and the milk fat globules are added into deionized water to be emulsified, and the anthocyanin emulsion type ingredient containing the milk fat globules is obtained; wherein anthocyanin in the ingredients and a fat membrane of the milk fat globules form a specific structure, and the specific structure is rich in long-chain unsaturated fatty acid and medium-chain fatty acid in a specific ratio of 1: (7-10) after being digested by in-vitro simulated gastrointestinal fluid. The anthocyanin ingredient containing the milk fat globules is a novel stable emulsion taking the natural milk fat globules as an anthocyanin carrier, is particularly suitable for being used as an ingredient of nutritional and healthy food, and is wide in application range. And the preparation method adopts a probe type ultrasonic combined high-speed shearing technology, so that the obtained emulsion is better in dispersity and stability, simple, efficient, green and safe.

The invention discloses an intestinal micro-emulsified targeted release type xanthoceras sorbifolia bunge oil soft capsule and a preparation method thereof, and belongs to the technical field of functional food and health-care product preparations. The soft capsule is composed of a content containing low-temperature squeezed xanthoceras sorbifolia bunge oil and a self-microemulsion delivery system, and a gastrointestinal fluid response type capsule shell. The preparation method comprises the steps of delivery system preparation, capsule shell preparation, capsule forming, quality detection and the like. Intestinal targeted delivery, controllable disintegration and intestinal in-situ emulsification core technologies are integrated to form a synergistic effect, so that active ingredients such as nervonic acid safely pass through the stomach and are accurately released in the intestinal tract to form a nano-scale microemulsion, the bioavailability is improved from less than 20% to more than or equal to 60%, and the nano-scale microemulsion is high in compatibility with an existing production line, controllable in quality, low in industrialization cost and suitable for industrial production. The xanthoceras sorbifolia bunge oil can be promoted to be upgraded to a high-valued functional preparation.

The invention relates to the field of gastrointestinal surgical nursing, and discloses a gastrointestinal fluid decompression device for gastrointestinal surgical nursing, which comprises a tank body, a negative pressure bottle body is arranged in the tank body, a pressure supplementing assembly is arranged on one side of the tank body, and a partition assembly is arranged above the pressure supplementing assembly. Through the deformation linkage design of the negative-pressure self-adaptive pressure supplementing assembly and the elastic negative-pressure bottle, real-time monitoring and dynamic compensation of the negative pressure in the negative-pressure bottle are achieved, the pressure supplementing strength can be automatically adjusted according to the springback unfolding degree of the negative-pressure bottle, the problems that the negative pressure of a traditional negative-pressure bottle is continuously attenuated, and pressure fluctuation is large are fundamentally solved, and the service life of the negative-pressure bottle is prolonged. And the whole gastrointestinal drainage process is kept in a stable, uniform and effective negative pressure state. The stable drainage pressure can avoid stimulation to gastrointestinal tracts of patients caused by sudden strong and weak suction, uncomfortable symptoms such as abdominal distension, nausea and reflux are remarkably reduced, drainage sufficiency of gastrointestinal fluid is improved, hydrops retention and related complication risks are reduced, and safer and more comfortable decompression guarantee is provided for postoperative recovery of the patients.

The application provides a lactobacillus gasseri strain A21120 with antioxidant, anti-inflammatory and antitumor functions, and a probiotic agent and application thereof, and belongs to the technical field of functional microorganisms. The strain A21120 is obtained by screening from intestinal feces of a centenarian healthy old person, and is identified by morphology and molecules and belongs to lactobacillus gasseri. The strain has good resistance to gastrointestinal fluid and bovine choline capacity, and has the potential to colonize the intestinal tract. The lactobacillus gasseri strain A21120 provided by the application has bacteriostatic, anti-inflammatory, antioxidant and antitumor activities, and provides a new way for the treatment of clinical related diseases, the development of drugs and the preparation of in vitro preparations or daily necessities.

The invention discloses lactobacillus rhamnosus and application thereof, the lactobacillus rhamnosus is named as lactobacillus rhamnosus, the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.35978, and the lactobacillus rhamnosus is preserved in the China General Microbiological Culture Collection Center on September 18, 2025. The strain has excellent alcohol tolerance and can survive in a 15% ethanol environment, and the degradation rate of the strain to a 10% ethanol solution in vitro reaches 17% or above; meanwhile, the strain has outstanding gastrointestinal fluid tolerance, and the survival rate of the strain treated in simulated gastric fluid with the pH value of 2.5 for 2 hours exceeds 93%. The strain and the fermentation product thereof also show remarkable antioxidant activity, and can effectively remove DPPH free radicals. The invention further provides application of the bacterial strain in preparation of products for dispelling effects of alcohol, protecting liver and resisting oxidation, and fermentation liquor, bacterial suspension and related compositions containing the bacterial strain, and the bacterial strain can be widely applied to the fields of functional foods, medicines and health-care products.

The present disclosure relates to a device for collecting gastrointestinal fluids / particles or samples. The present disclosure also relates to a process of collecting gastrointestinal fluids / particles or samples by the ingestible device. The ingestible device of the present disclosure is designed to non-invasively collect gastrointestinal particles, including biomolecules and components of the residing gut microbiome, with precise spatial resolution along the gastrointestinal (GI) tract. Upon deployment, the device's design and / or actuation mechanism facilitates the capture of gastrointestinal fluids and associated particles within those fluids. These samples are securely stored within the device until its natural egestion, after which the collected material can be subjected to further bio / chemical analyses.

This invention relates to the application of a melanin-catalase nanocomposite (MAC) targeting intestinal mucosal neutrophils in the preparation of drugs for treating inflammatory bowel disease, belonging to the field of novel applications of nanomedicine. It addresses the challenges of catalase oral delivery being easily degraded and inactivated by gastrointestinal proteases and difficult to precisely target neutrophils. This invention is the first to discover a MAC prepared by in-situ polymerization of dopamine on the surface of catalase, which can be used for the treatment of inflammatory bowel disease. This nanocomposite, through oral delivery, precisely targets intestinal mucosal infiltrating neutrophils and maintains structural stability in the gastrointestinal fluid environment, effectively protecting catalase activity. It actively targets intestinal mucosal infiltrating neutrophils through the high affinity of melanin for dopamine D2 receptors, synergistically exerting a triple effect of hydrogen peroxide decomposition, hypochlorous acid scavenging, and iron ion chelation, effectively inhibiting the formation of extracellular traps in neutrophils.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

This invention discloses a sustained-release granule of traditional Chinese medicine and its preparation method, relating to the field of traditional Chinese medicine preparation technology. It is prepared from the following materials in parts: 100-600 parts of active extract of traditional Chinese medicine, 50-450 parts of beeswax, 20-400 parts of aralia elata gelatin, 22-400 parts of modified gelatin, 15-50 parts of polyphosphate ester, 20-220 parts of sepiolite, 10-120 parts of ethyl cellulose aqueous dispersion and 5-30 parts of calcium phosphate salt. This invention uses beeswax as a hydrophobic sustained-release barrier, which can effectively inhibit the rapid dissolution of drugs in the early stage, avoiding gastrointestinal irritation and drug efficacy fluctuations caused by a sudden increase in blood drug concentration after administration. Combined with a hydrophilic gel skeleton composed of aralia elata and modified gelatin, it slowly swells and erodes upon contact with gastrointestinal fluid, achieving a stable release of drugs in the early and middle stages. At the same time, ethyl cellulose aqueous dispersion forms a dense hydrophobic coating film, which precisely controls the drug release rate in the later stage. The multiple sustained-release mechanisms work together to overcome the poor adaptability of traditional systems and effectively avoid the problems of sudden release, delayed release, and incomplete drug release.

The invention discloses a combined modular multifunctional stomach decompression jejunum nutrition tube assembly, which relates to the field of medical instruments and comprises a tube body, a first joint, a second joint, a jejunum tube, a suction tube and a pressure adjusting tube. The tube body is formed by connecting a first tube body and a second tube body, the interior of the tube body is divided into a first tube cavity and a second tube cavity which are independent of each other through an arc-shaped partition plate, the first connector and the second connector are inserted into a connector in the top of the tube body in an interchangeable mode, and the suction tube and the pressure adjusting tube penetrate through the first connector to be communicated with the first tube cavity. The second connector is used for fixing a jejunum tube which penetrates through the second tube cavity and is led out from the bottom through hole. Gastrointestinal fluid regurgitation and cross contamination are fundamentally prevented through the tube cavity separation design, the modular structure allows flexible configuration of single or composite functions according to clinical requirements, and meanwhile, the integrated pressing rotary type locking mechanism can stably and conveniently fix and adjust the jejunum tube; and the reliability and the safety of treatment are obviously improved.

Lactiplantibacillus plantarum JN-7, a bacterial powder, a preparation method, a probiotic composition and the use thereof. According to the present application, a new strain of Lactiplantibacillus plantarum named Lactiplantibacillus plantarum JN-7 with the deposit number of CGMCC No. 30605 is obtained by means of screening. By means of basic characteristic analysis (growth curve, acid resistance, bile salt resistance, and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic capacity, toxigenic capacity, and cytotoxicity), adhesion evaluation, anti-inflammatory effect evaluation, production performance evaluation (fermentation yield and lyophilization yield), and stability tests (an accelerated storage stability test) of this strain, it is found that Lactiplantibacillus plantarum JN-7 is a safe strain with an excellent production performance, high stability, and an anti-inflammatory efficacy. The bacterial powder produced therefrom can remain stable and active for a long time.

The invention discloses application of common turnip polysaccharide in preparation of a product for preventing alcoholic liver injury and assisting in dispelling the effects of alcohol, and belongs to the technical field of natural product development and biological medicine. The common turnip polysaccharide prepared through ultrasonic and alcohol extraction is rich in galactose and rhamnose, has high galacturonic acid content, shows typical RG-I type pectic polysaccharide characteristics, can be kept stable in simulated gastrointestinal fluid and directly reaches the colon to play a role; meanwhile, the prepared common turnip polysaccharide can remarkably reduce transaminase increase and lipid accumulation caused by alcohol, and by specifically proliferating beneficial bacteria such as Akkermansia and the like, the intestinal barrier is repaired, and endotoxin is prevented from entering blood; meanwhile, liver hangover alleviating enzymes can be obviously activated, and the drunkenness time is shortened.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus rhamnosus A25040 with an antibacterial function as well as a preparation and application of the lactobacillus rhamnosus A25040. The lactobacillus rhamnosus A25040 provided by the invention has the advantages that the lactobacillus rhamnosus A25040 can be used for treating enteropathogenic bacteria, gastrointestinal pathogenic bacteria and oral pathogenic bacteria; particularly, the antibacterial and bactericidal effects on escherichia coli, helicobacter pylori, staphylococcus aureus, fusobacterium nucleatum, porphyromonas gingivalis, streptococcus mutans, streptococcus gordoni, streptococcus sanguis, streptococcus mitis, streptococcus suvidensis subspecies and streptococcus suvidensis subspecies are relatively strong; active substances secreted by the strain have good thermal stability, enzyme tolerance and gastrointestinal fluid tolerance, and the strain shows excellent oxidation resistance. The lactobacillus rhamnosus A25040 disclosed by the invention has broad-spectrum bacteriostasis and oxidation resistance, does not have hemolysis capacity, can be widely applied to functional food development, and has important application value in the field of biological medicines and daily chemical products.

The preparation method comprises the following steps: modifying lysine-proline-valine on phosphatidylserine active ester to obtain an anionic liposome, forming a liposome membrane by using the anionic liposome and cholesterol, and then uniformly coating a layer of liposome on the outer layer of each probiotic cell by using calcium ion mediation to realize single cell coating, so that a single cell is obtained; a probiotic oral delivery system is obtained. According to the probiotic oral delivery system, coating of probiotic single cells can be achieved, and meanwhile the survival rate of the probiotics is not affected by a coating method in the coating process. In addition, the probiotic oral delivery system provided by the invention can effectively improve the viability of the probiotics in gastrointestinal fluid, increase colonization of the probiotics in intestinal tracts, target inflammation parts in the intestinal tracts, effectively reverse DSS-induced colon injury, reduce inflammatory cell infiltration and recover crypts and mucous membrane layers; the expression of proinflammatory factors is obviously reduced, and the expression of anti-inflammatory factors is improved.

Disclosed in the present invention are a Lactiplantibacillus plantarum strain JN9, a preparation, a probiotic composition and the use thereof. The present application finds a novel Lactiplantibacillus plantarum strain JN9 by means of screening, and the accession number thereof is: CCTCCNO: M20241647c. By means of analysis of basic characteristics of the strain (growth curve, acid tolerance, bile salt tolerance and gastrointestinal fluid tolerance), safety evaluation (antibiotics sensitivity, hemolysis capacity, toxin production capacity, cytotoxicity and bioamine production capacity), adhesion evaluation, GABA production evaluation, alcohol tolerance evaluation and acetaldehyde dehydrogenase production capability evaluation, said strain is found to be a safe strain, and exhibits GABA production performance, alcohol tolerance and acetaldehyde dehydrogenase activity

The invention discloses a compound paracetamol and amantadine hydrochloride capsule containing caffeine microcapsules, which relates to the technical field of medicines and comprises paracetamol, amantadine hydrochloride, calculus bovis factitius, pharmaceutic adjuvants and functional microcapsule units. The functional microcapsule unit has a three-layer structure: a core material taking caffeine and microcrystalline cellulose as a core, an ethyl cellulose controlled release layer and a quick release layer containing chlorpheniramine maleate. According to the structure, time sequence controlled release of drugs is achieved by synthesizing a polymer coating material, chlorpheniramine maleate is quickly released when encountering gastrointestinal fluid to quickly resist allergy, and caffeine starts to be slowly released after being effectively delayed to the intestinal environment, so that the time when the plasma concentration reaches the peak tends to be synchronous with the time when chlorpheniramine maleate reaches the peak; the drowsiness side effect can be effectively resisted.

A process for removing Pb2+ ions from fluids is disclosed. More particularly, an intracorporeal process for removing Pb2+ ions from gastrointestinal fluids is disclosed. The process involves contacting gastrointestinal fluid with a titanate-based ion exchanger represented by the empirical formula: AmTiOz where A is sodium, potassium, lithium, magnesium, calcium, hydronium, or mixtures thereof. The alkali titanate ion exchanger is synthesized from specific Ti reagents, including nano-sized TiO2 and preformed spray dried TiO2 spheres, that impart properties such as favorable particle size and particle size distributions that are beneficial for treating the body.

The invention belongs to the field of life health, and particularly relates to preparation and application of a life metal synanthrin chelate which comprises life metal elements and synanthrin. Wherein the synanthrin is subjected to bifunctional modification, and the bifunctional modification comprises carboxymethylation and phosphorylation respectively; the life metal elements comprise calcium, iron, zinc, selenium and magnesium, the molar ratio of synanthrin to the life metal elements in the life metal synanthrin chelate is 1: (0.01-1), the substitution degree of carboxymethyl is 0.2-0.8, and the substitution degree of phosphate is 0.01-0.3. The synanthrin is subjected to carboxymethylation and phosphorylation bifunctional modification, the stable chelate is formed by the synanthrin and life metal elements, the life metal synanthrin chelate is excellent in stability in a simulated gastrointestinal fluid environment, controllable slow release of the life metal elements can be achieved, and meanwhile, the life metal synanthrin chelate can be used for improving the bioavailability of the gastrointestinal fluid by means of the prebiotic characteristic of the synanthrin. And the absorption and utilization rate of life metal elements in intestinal tracts is greatly improved.